Australia cannot compete with manufacturing and R&D incentives being offered by countries such as China and Singapore, Innovation Minister Senator Kim Carr has said
» full reportThe largest-ever trial of patients with heart failure - including Australian subjects - has shown that adding Servier's heart rate lowering medication ivabradine to standard therapies significantly reduced the risk of hospitalisation and death
» full reportA majority of local biotechs has posted net losses for the financial year ending 30 June 2010, with a large percentage posting a greater loss than in the same period a year earlier
» full reportMelbourne-based Clinuvel Pharmaceuticals has announced it will begin a pilot trial in October of its photoprotective drug,
Scenesse in patients suffering from the pigmentary disorder vitiligo, made famous by the King of Pop Michael Jackson
» full reportA trial testing Roche's experimental cancer drug PLX4032 has caused significant excitement in the research community as a possible treatment for metastatic melanoma tumours with a specific genetic signature
» full reportJapanese pharmaceutical company Eisai has announced successful results from a Phase III trial of its investigational drug perampanel in epilepsy, with plans on track for applications to regulators in 2011
» full reportGlaxoSmithKline (GSK) has launched a Phase III trial of a vaccine to prevent shingles, which if successful, will compete with Merck's
Zostavax. The 30,000 patient trial includes local sites
» full reportCelgene has initiated a local trial of its myelodysplastic syndrome(MDS) treatment,
Vidaza, not it says to prove efficacy, but for ethical and safety reasons until the drug becomes commercially available in Australia
» full reportNovartis has launched a clinical trial of its novel Hepatitis C vaccine,
Debio 025, with multiple Australian study sites
» full report
